Revenue: As of FY2026 Q2, the actual value is USD 1.443 M.

EPS: As of FY2026 Q2, the actual value is USD -2.09.

EBIT: As of FY2026 Q2, the actual value is USD -496 K.

Segment Revenue

Product revenue for Arcadia Biosciences, Inc. was $1,443 thousand for the three months ended June 30, 2026, a slight decrease from $1,455 thousand for the same period in 2025. Total revenues also decreased to $1,443 thousand for the three months ended June 30, 2026, from $1,455 thousand in 2025. For the six months ended June 30, 2026, product revenue was $2,543 thousand, down from $2,655 thousand in 2025. Total revenues for the first half of 2026 were $2,543 thousand, compared to $2,655 thousand in 2025. The decline in total revenues for the second quarter of 2026 was - $12,000 or -1% compared to the second quarter of 2025, and for the first half of 2026, it was - $112,000 or -4% from the first half of 2025, primarily due to low inventory balances and longer shipping times.

Operational Metrics

Cost of revenues for the three months ended June 30, 2026, was $812 thousand, a decrease from $824 thousand in the prior year. For the six months ended June 30, 2026, cost of revenues was $1,512 thousand, up from $1,506 thousand in 2025. Research and development expenses were $0 thousand for both the three and six months ended June 30, 2026, down from $9 thousand in both periods in 2025. Selling, general and administrative (SG&A) expenses decreased to $1,127 thousand for the three months ended June 30, 2026, from $2,123 thousand in 2025. For the six months ended June 30, 2026, SG&A expenses were $2,306 thousand, a reduction from $3,861 thousand in 2025. SG&A expenses declined by $1.0 million in the second quarter of 2026 and $1.6 million in the first half of 2026 compared to the same periods in 2025, mainly due to lower employee costs and the absence of M&A fees. Total operating expenses for the three months ended June 30, 2026, were $1,939 thousand, compared to $1,956 thousand in 2025. For the six months ended June 30, 2026, total operating expenses increased to $3,818 thousand from $2,626 thousand in 2025. Other operating expenses decreased by $1.0 million in the second quarter of 2026 due to a $1.0 million gain from the elimination of a contingent liability in the second quarter of 2025. For the first half of 2026, other operating expenses decreased by $2.8 million, attributed to a $2.0 million gain from contingent liability elimination and a $750,000 gain from the sale of intangible assets in the first half of 2025.Loss from continuing operations for the three months ended June 30, 2026, was - $496 thousand, an improvement of $5,000 or 1% compared to - $501 thousand in 2025. For the six months ended June 30, 2026, loss from continuing operations was - $1,275 thousand, a decrease of - $1,304 million or -4497% from an income of $29 thousand in 2025.Net loss attributable to common stockholders for the three months ended June 30, 2026, was - $6,266 thousand, compared to - $4,458 thousand in 2025. For the six months ended June 30, 2026, the net loss attributable to common stockholders was - $10,651 thousand, an increase from - $1,859 thousand in 2025.

Cash Flow

Net cash used in operating activities for the six months ended June 30, 2026, was - $1,418 thousand, an improvement from - $3,621 thousand used in the same period in 2025. Net cash used in operating activities for the second quarter of 2026 was - $319,000. Net cash provided by investing activities for the six months ended June 30, 2026, was $0 thousand, a decrease from $750 thousand provided in 2025. Net cash provided by financing activities for the six months ended June 30, 2026, was $5,337 thousand, significantly higher than $5 thousand provided in 2025. This included $4,000 thousand from the June 2026 PIPE and $2,082 thousand from the January 2026 Inducement Offer.

Cash and Cash Equivalents

Cash and cash equivalents at the end of the period, June 30, 2026, increased to $4,178 thousand from $1,376 thousand at the end of the six months ended June 30, 2025. At December 31, 2025, cash and cash equivalents were $259 thousand. The company ended the second quarter of 2026 with a cash balance of $4.2 million.

Balance Sheet Highlights

Total assets as of June 30, 2026, were $5,893 thousand, down from $6,546 thousand as of December 31, 2025. Total liabilities increased to $5,260 thousand as of June 30, 2026, from $2,406 thousand as of December 31, 2025. Total stockholders’ equity decreased to $633 thousand as of June 30, 2026, from $4,140 thousand as of December 31, 2025. The accumulated deficit grew to - $291,868 thousand as of June 30, 2026, from - $281,217 thousand as of December 31, 2025.

Unique Metrics

Arcadia Biosciences, Inc. reported a valuation loss on the June 2026 PIPE of - $5,423 thousand for both the three and six months ended June 30, 2026. A loss on the January 2026 Inducement Offer of - $2,877 thousand was recorded for the six months ended June 30, 2026. The change in fair value of common stock warrant and option liabilities resulted in a gain of $3,083 thousand for the three months ended June 30, 2026, and a gain of $4,274 thousand for the six months ended June 30, 2026. Issuance and offering costs were - $651 thousand for the three months ended June 30, 2026, and - $1,072 thousand for the six months ended June 30, 2026. The net loss for the second quarter of 2026 included a - $2.8 million unrealized loss related to Above Food stock, a - $5.4 million valuation loss from the June 2026 PIPE financing, and $651,000 in offering costs, partially offset by a gain from the change in fair value of common stock warrant and option liabilities. The second quarter of 2025 included a - $4.5 million credit loss on a note receivable from Above Food, offset by a $1.1 million unrealized gain on Above Food stock.For the first half of 2026, the net loss included a - $4.3 million unrealized loss on Above Food stock, a - $2.9 million loss from the January 2026 inducement offer financing, a - $5.4 million valuation loss on the June 2026 PIPE, and $1.1 million in offering costs, partially offset by a $4.3 million gain from the change in fair value of common stock warrant and option liabilities. The first half of 2025 included a - $4.5 million credit loss on a note receivable from Above Food, offset by a $1.1 million unrealized gain on Above Food stock and a $1.3 million gain from the change in fair value of common stock warrant and option liabilities.

Outlook / Guidance

Arcadia Biosciences, Inc. anticipates Zola’s growth to accelerate, driven by new product introductions. The company plans to launch a 1-liter espresso with a new formula in Q4 2026, which has pre-launch commitments from its two largest customers. Additionally, three new products are planned for launch in the first half of 2027.